74 139

Cited 0 times in

Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

Authors
 Young-Hwan Ahn  ;  Heirim Lee  ;  Do Young Kim  ;  Hye Won Lee  ;  Su Jong Yu  ;  Young Youn Cho  ;  Jeong Won Jang  ;  Byoung Kuk Jang  ;  Chang Wook Kim  ;  Hee Yeon Kim  ;  Hana Park  ;  Hyo Jung Cho  ;  Bumhee Park  ;  Soon Sun Kim  ;  Jae Youn Cheong 
Citation
 GUT AND LIVER, Vol.15(3) : 410-419, 2021-05 
Journal Title
GUT AND LIVER
ISSN
 1976-2283 
Issue Date
2021-05
Keywords
Antiviral agents ; Carcinoma ; Hepatitis C ; Recurrence ; Risk factors ; chronic ; hepatocellular
Abstract
Background/aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence.

Methods: A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results.

Results: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (<12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (<12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 3.73, p<0.001; HR 3.34, p<0.001; and HR 1.74, p=0.006; respectively).

Conclusions: DAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (<12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy.
Files in This Item:
T202103005.pdf Download
DOI
10.5009/gnl20151
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Do Young(김도영)
Lee, Hye Won(이혜원) ORCID logo https://orcid.org/0000-0002-3552-3560
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/184428
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links